The Goldman Sachs Group Initiates Coverage on Lantheus (NASDAQ:LNTH)

Stock analysts at The Goldman Sachs Group started coverage on shares of Lantheus (NASDAQ:LNTH - Get Free Report) in a research report issued on Wednesday, Marketbeat Ratings reports. The firm set a "buy" rating and a $143.00 price target on the medical equipment provider's stock. The Goldman Sachs Group's target price would suggest a potential upside of 56.88% from the stock's current price.

LNTH has been the subject of a number of other reports. JMP Securities lowered their price objective on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research report on Thursday, November 7th. StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. Redburn Atlantic began coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective for the company. Finally, Truist Financial reiterated a "buy" rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $131.86.

Lantheus Stock Performance

Shares of NASDAQ LNTH traded down $1.51 during trading hours on Wednesday, hitting $91.15. 1,413,065 shares of the stock were exchanged, compared to its average volume of 1,013,360. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The company has a market cap of $6.34 billion, a PE ratio of 15.17 and a beta of 0.45. The company's fifty day simple moving average is $97.31 and its two-hundred day simple moving average is $98.28.

Institutional Trading of Lantheus

A number of institutional investors have recently bought and sold shares of LNTH. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus in the 3rd quarter worth about $25,000. Signaturefd LLC grew its stake in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 92 shares during the period. UMB Bank n.a. increased its holdings in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 126 shares in the last quarter. Kathleen S. Wright Associates Inc. acquired a new position in Lantheus in the third quarter valued at approximately $51,000. Finally, GAMMA Investing LLC boosted its holdings in shares of Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after buying an additional 146 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.